info@imoveflu.org

Login

Protocols

Protocols

Below are the generic I-MOVE protocols for various outcomes and study designs. If you are part of the I-MOVE multicentre study teams, please go to the hospital network or primary care network pages for study site-specific protocols (for which access is restricted).

Primary care generic protocolI-MOVE primary care multicentre study generic protocol (influenza vaccination)

​This is the I-MOVE primary care test-negative design multicentre study generic protocol. Study sites can use this protocol together with study site-specific annexes. This protocol also covers the pooled analysis.

Primary care generic protocolI-MOVE hospital multicentre study generic protocol (influenza vaccination)

​This is the I-MOVE hospital test-negative design multicentre study generic protocol. Study sites can use this protocol together with study site-specific annexes. This protocol also covers the pooled analysis.

Primary care generic protocolI-MOVE laboratory generic protocol (influenza)

In this I-MOVE laboratory generic protocol, we outline procedures to attempt to obtain a representative sample of viruses to sequence (which includes random selection).

Primary care generic protocolI-MOVE+ generic protocol for screening method (influenza vaccination)

This is the generic protocol for measuring influenza vaccine effectiveness among the elderly population using the screening method in the European Union and European Economic Area Member States. This protocol was created as part of the I-MOVE+ project (2015–18).

Primary care generic protocolI-MOVE+ generic protocol for impact (influenza vaccination)

This is the generic protocol for measuring the impact of influenza vaccination programmes among the elderly population in the European Union and European Economic Area Member States. This protocol was created as part of the I-MOVE+ project                           (2015–18).

I-MOVE+ primary care generic protocol among those aged 65 years and olderI-MOVE+ primary care generic protocol (influenza vaccination)

This is the generic protocol for measuring the seasonal and pandemic influenza vaccine effectiveness among the elderly population in the European Union and European Economic Area Member States. This protocol was created as part of the I-MOVE+ project (2015–18).

I-MOVE+ primary care generic protocol among those aged 65 years and olderGeneric protocol on enhanced surveillance for invasive pneumococcal disease at the EU/EEA level

This generic protocol proposes a uniform approach for active IPD surveillance in children and enhanced surveillance in other age groups. This protocol was created as part of the I-MOVE+ project (2015–18).

I-MOVE+ primary care generic protocol among those aged 65 years and olderGeneric protocol for population-level impact analysis on pneumonia at the EU/EEA level

This protocol presents a generic approach for conducting PCV impact studies on pneumonia among older adult population by using the before and after design with hospital discharge data bases in Europe.

I-MOVE+ primary care generic protocol among those aged 65 years and olderGeneric protocol for vaccine effectiveness against invasive pneumococcal disease and/or pneumococcal community acquired pneumonia at the EU/EEA level

This protocol presents a generic approach for conducting vaccine effectiveness studies using the indirect cohort method (also called case only or Broome method) in older adults.

I-MOVE+ primary care generic protocol among those aged 65 years and olderGeneric protocol for conducting before and after studies on invasive pneumococcal disease and pneumococcal pneumonia at the EU/EEA level

This protocol presents a generic approach for conducting pneumococcal conjugate vaccine impact studies on invasive pneumococcal disease and pneumococcal pneumonia in the older adult population by using the before and after design with data provided by several routine surveillance systems in Europe.